PRRT2 and lymphoma: In addition, mitoxantrone, a firmly established inhibitor of type II topoisomerase and protein kinase C (PKC), is reported to exert its anti-cancer effect in lymphomas, leukemias, and breast, colorectal, and prostate cancers (90–97).